Literature DB >> 12592066

Preoperative findings in non-gynecologic carcinomas metastasizing to the ovaries.

Fumitaka Kikkawa1, Kiyosumi Shibata, Kazuhiko Ino, Seiji Nomura, Hiroaki Kajiyama, Takahiro Suzuki, Michiyasu Kawai, Shigehiko Mizutani.   

Abstract

This study evaluated whether preoperative findings are useful prognostic indicators in patients with non-gynecologic carcinomas metastasizing to the ovaries. Fifty-three patients were analyzed. Primary sites of carcinoma were discovered after gynecologic surgery in 20 patients. In 10 patients, primary sites of carcinoma were discovered during gynecologic surgery. Thirty-one patients received surgery on the primary site before gynecologic surgery. The primary site could not be identified in 2 patients. The 5-year survival rate was 40.0% in patients, who underwent surgery on the primary site before gynecologic surgery. However, the 5-year survival rate was 12.2% in patients, who underwent surgery on the primary site during or after gynecologic surgery. The CEA level was significantly lower in the stomach primary group than in the intestine primary group. However, CA125 was the only marker significantly affecting survival. In comparison with primary ovarian carcinoma, the sensitivity of CEA was significantly higher for non-gynecologic ovarian carcinoma, while that of CA125 was significantly less sensitive for non-gynecologic ovarian carcinoma. In conclusion, the prognosis was better in patients, who had undergone resection of primary carcinoma before gynecologic surgery on non-gynecologic ovarian carcinoma. CEA is a useful marker to distinguish non-gynecologic from primary ovarian carcinoma, while CA125 is the only significant prognostic marker for non-gynecologic ovarian carcinoma. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12592066     DOI: 10.1159/000068388

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  7 in total

1.  A 26-year-old female with metastatic primary gastrointestinal malignancy presenting as menorrhagia.

Authors:  Maliha Khan; Ravinder Pal Bhatti; Sarbajit Mukherjee; Alaa M Ali; Alan D Gilman; Aibek E Mirrakhimov; Nkemakolam Iroegbu
Journal:  J Gastrointest Oncol       Date:  2015-04

2.  Dyspnoea and the ovaries: a rare presentation of Krukenberg tumour.

Authors:  Wasiq Faraz Rawasia; Udit Chaddha; Karim El-Kersh; Rafael L Perez
Journal:  BMJ Case Rep       Date:  2013-02-01

3.  "Ovarian Metastases from Colorectal Cancer: Our Experience".

Authors:  Vasu Reddy Challa; Y G Basavana Goud; Poornima Rangappa; Vijayalakshmi Deshmane; K V Veerendra Kumar; B A Madhusudhana
Journal:  Indian J Surg Oncol       Date:  2014-12-27

Review 4.  The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review.

Authors:  Ondřej Kubeček; Jan Laco; Jiří Špaček; Jiří Petera; Jindřich Kopecký; Alena Kubečková; Stanislav Filip
Journal:  Clin Exp Metastasis       Date:  2017-07-20       Impact factor: 5.150

5.  Palliative surgery for Krukenberg tumors - 12-year experience and review of the literature.

Authors:  Isaac Seow-En; Gwen Hwarng; Grace Hwei Ching Tan; Leonard Ming Li Ho; Melissa Ching Ching Teo
Journal:  World J Clin Oncol       Date:  2018-02-10

6.  Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis.

Authors:  Qingyi Wang; Xiaoling Feng; Xiaofang Liu; Siyu Zhu
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

7.  Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells.

Authors:  Mikio Terauchi; Hiroaki Kajiyama; Kiyosumi Shibata; Kazuhiko Ino; Akihiro Nawa; Shigehiko Mizutani; Fumitaka Kikkawa
Journal:  BMC Cancer       Date:  2007-07-27       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.